More Information

In July 2011, Gilead granted our Indian pharmaceutical company partners and the Medicines Patent Pool future rights to manufacture and sell generic versions of three investigational HIV therapies currently completing late-stage clinical development. These rights are granted subject to these products completing clinical trials successfully and receiving the appropriate U.S. regulatory approvals.

The investigational pipeline medicines covered in these licensing agreements are:

• Elvitegravir, a member of the class of antiretrovirals known as integrase inhibitors
• Cobicistat, an antiretroviral boosting agent that could allow for once-daily dosing of elvitegravir, and other medicines such as protease inhibitors
• The "Quad," which combines four Gilead HIV medicines (elvitegravir, cobicistat and the two components of Truvada®) into a once-daily, single-tablet regimen

By granting these rights now, we aim to ensure that high quality, low-cost versions of new therapies can be made available in developing countries as quickly as possible following initial regulatory approval.

Gilead licensed rights to commercialize elvitegravir from Japan Tobacco (JT), and JT has worked in close partnership with Gilead to ensure access to elvitegravir in the developing world.